Plasmodium Vivax Infection Dynamics and Control

Plasmodium vivax remains a leading cause of malaria outside sub-Saharan Africa, distinguished by its capacity to form dormant liver stages (hypnozoites) that can reactivate weeks to months after initial clearance. These relapses sustain transmission, complicate case management and challenge elimination efforts. Transmission dynamics are influenced by geographic variation in relapse periodicity, vector ecology and human movement. Control strategies centre on blood-stage treatment combined with radical cure to clear hypnozoites, vector control measures such as insecticide-treated nets and indoor residual spraying, and strengthened diagnostic capacity to detect low-density or asymptomatic infections. Mathematical and probabilistic models have become essential for quantifying the size and impact of the hypnozoite reservoir, predicting rebound risks and evaluating intervention combinations. Innovations in point-of-care diagnostics and safer single-dose therapies aim to improve adherence and mitigate risks in populations with glucose-6-phosphate dehydrogenase deficiency. A coordinated approach that integrates chemotherapeutic, serological, entomological and modelling insights is critical to advancing towards regional elimination of this resilient parasite.

Research from Nature Portfolio

Recent probabilistic frameworks have combined genetic fingerprinting with time-to-event modelling to distinguish relapses from recrudescence and new infections. By integrating identity-by-descent metrics and longitudinal follow-up data, these models provide individual-level probabilities of relapse and reveal that supervised high-dose radical cure can reduce relapse rates from three in four untreated cases to one in forty. This enhanced classification supports targeted radical cure regimens and informs surveillance strategies in areas of frequent relapse.

Individual-based transmission models calibrated to high-burden settings have examined the impact of scaling up interventions such as bed-net coverage, case management and mass drug administration. Simulations indicate that vector control alone can suppress prevalence but may risk rebound once measures are relaxed, whereas combining blood- and liver-stage therapies yields more durable reductions. These analyses underscore the necessity for sustained intervention packages and guide policy on the optimal sequencing and intensity of control measures to achieve elimination thresholds.

Plasmodium Vivax Infection Dynamics and Control publication trend

The graph below shows the total number of articles in plasmodium vivax infection dynamics and control across all publications each year (not limited to Nature Index journals).

Technical terms

Hypnozoite: Dormant liver-stage form of P. vivax responsible for relapses.

Relapse: Recurrence of blood-stage infection arising from activation of hypnozoites.

Radical cure: Therapeutic regimen aimed at eradicating both blood and liver stages of the parasite.

Primaquine: An 8-aminoquinoline antimalarial used for radical cure targeting hypnozoites.

G6PD deficiency: Genetic enzyme deficiency that increases risk of haemolysis under 8-aminoquinoline treatment.

Serological test-and-treat: Intervention using antibody-based diagnostics to identify and treat asymptomatic hypnozoite carriers.

References

1. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nature Communications (2019).
2. Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nature Communications (2018).
3. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. The Lancet (2023).
4. Accelerating towards P. vivax elimination with a novel serological test-and-treat strategy: a modelling case study in Brazil. The Lancet Regional Health - Americas (2023).
5. Mathematical models of Plasmodium vivax transmission: A scoping review. PLOS Computational Biology (2024).